Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 28, 2019 (the Effective Date), Protagonist Therapeutics, Inc. (the Company) appointed Donald Kalkofen as Chief Financial Officer to serve as the Companys principal financial officer and principal accounting officer. Dinesh V. Patel, Ph.D., the Companys President and Chief Executive Officer, had served as interim principal financial officer from January 11, 2019 until the Effective Date and had served as interim principal accounting officer from March 20, 2019 until the Effective Date.
Mr. Kalkofen, age 55, had served in a consulting capacity as the Companys Senior Advisor, Finance since February 11, 2019 until his appointment as Chief Financial Officer, and previously served in a consulting capacity as Interim Controller of the Company from May 2018 to June 2018. Mr. Kalkofen served as Interim Chief Financial Officer of App Annie, Inc., a late-stage global SaaS company, from June 2018 to January 2019. From November 2017 until April 2018, he served as a Financial Consultant at Depomed, Inc. (now Assertio Therapeutics, Inc.), a specialty pharmaceutical company. Mr. Kalkofen also served as a Chief Financial Officer consulting partner at Hardesty, LLC, a financial executive consulting and talent firm, from July 2018 to November 2017. Mr. Kalkofen served at Align Technology, Inc., a global medical device company, as Interim Assistant Controller from May 2016 to October 2017. Prior to his time at Align Technology, Mr. Kalkofen served as a Financial Consultant at Marketo, Inc., a marketing software company from March 2016 to May 2016. Immediately prior to joining Marketo, Mr. Kalkofen served as President and Vice President of Finance, Consultant at Simplifier Corporation, a SaaS expense reporting solutions company, which he co-founded in October 2014. Prior to co-founding Simplifier Corporation, Mr. Kalkofen served as a finance consultant at Symantec Corporation, a cybersecurity software company, from 2012 through December 2013 and as Director of Accounting from January 2014 until October 2014. Mr. Kalkofen began his career at PricewaterhouseCoopers LLP as part of the firms audit practice group. Mr. Kalkofen holds a B.A. in Accounting from Washington State University, is an active Certified Public Accountant and Certified Global Management Accountant and brings over 15 years of Chief Financial Officer experience.
The Company has entered into an offer letter with Mr. Kalkofen (the Offer Letter) pursuant to which he will be paid an annual base salary of $350,000 (the Base Salary) and will be eligible for a discretionary annual bonus of up to 40% of his Base Salary. In addition, the Compensation Committee of the Board of Directors (the Compensation Committee) granted Mr. Kalkofen an option to purchase 100,000 shares of the Companys Common Stock (the Option) as of May 31, 2019 (the Option Grant Date). The shares subject to the Option will vest over four years, with 25% of the Option shares vesting on the one-year anniversary of the Option Grant Date, and the balance vesting in equal monthly installments over the following 36 months, in each case subject to Mr. Kalkofens continued service with the Company. The Option is subject to the terms of the Companys 2018 Inducement Plan and Mr. Kalkofens option agreement.
The foregoing description of the Offer Letter is a summary and does not purport to be complete. Such description is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
2